The content of this website is intended for United States audiences only.

Report an Adverse Event
/-/media/project/gileadclinicaltrial/header/arrow-right-img.svg

Gilead Reinforces Their Commitment to Gynecologic Health

At Gilead, we recognize the significance of gynecologic health and are actively supporting and enhancing efforts in this field. Through our extensive research and clinical trials, we aim to better understand, prevent, and treat endometrial, cervical, and ovarian cancers. Our commitment to clinical trials ensures that we remain at the forefront of scientific discovery and therapeutic advancement.

Navigating gynecologic cancers

Endometrial cancer

Ovarian cancer

Cervical cancer

Recruiting trials

According to the American Cancer Society, there were about

117,000

new gynecologic cancer diagnoses

in 2024 in the United States

Source: American Cancer Society

Different types of gynecologic cancers

Gynecologic cancer is a condition where the cells in a woman's reproductive system start to grow uncontrollably.

This can happen in any of the 5 main areas of the female reproductive system:

What is endometrial cancer?

What is endometrial cancer?

Endometrial cancer is the most common type of gynecologic cancer in the United States. The number of cases has been rising steadily over the last 10 years. Each year, there was about a 1% increase in endometrial cancers in White women and a 2% to 3% increase among women of all other racial and ethnic groups.

Endometrial cancer is a condition where the cells in the lining of the uterus grow more than they should. The uterus is the part of a woman's body, located in the lower belly area between the hips. Symptoms of endometrial cancer may include abnormal vaginal bleeding or pelvic pain.

Sources: National Cancer Institute, American Cancer Society, Centers for Disease Control and Prevention

Risk factors include the following:

  • Aged 50 years and older
  • Being a Black woman
  • Obesity
  • Having metabolic syndrome or type 2 diabetes
  • Taking estrogen or tamoxifen
  • Family history of endometrial, colon, or ovarian cancer
Sources: Centers for Disease Control and Prevention, National Cancer Institute, American Cancer Society

What is ovarian cancer?

What is ovarian cancer?

Ovarian cancer is commonly diagnosed in women between 55 and 64 years old. White, non-Hispanic American Indian, and Alaska Native women are at a higher risk compared to Black, non-Hispanic Asian/Pacific Islander, and Hispanic women.

Ovarian cancer is a condition where cells in the ovaries, fallopian tubes, or peritoneum start to grow more than they should. Unlike cervical cancer, the cause of most ovarian cancers is unknown. Symptoms of ovarian cancer may include bloating, pain in the pelvic area (between the stomach and thighs), trouble eating or feeling full quickly, or urinary symptoms such as constant need to urinate or frequent urination.

Risk factors include the following:

  • Family history of the disease
  • Carrying a BRCA1 or BRCA2 genetic mutation
  • Being of Eastern European or Ashkenazi Jewish descent
  • Having endometriosis
  • Experiencing fertility problems
Sources: American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, American Cancer Society, American Cancer Society, American Cancer Society, MedlinePlus

What is cervical cancer?

What is cervical cancer?

Cervical cancer is commonly diagnosed in women between 35 and 44 years of age. Black and Native American women have a 65% higher risk of death from cervical cancer compared to White women. Despite a 1.7% annual increase in cases for women aged 30-44 years from years 2012-2019, the 20-24 years age group shows promise with an 11% annual decrease, likely due to the HPV vaccination.

Cervical cancer is a condition where cells in the cervix start to grow more than they should. The main cause is a long-lasting infection with human papillomavirus (HPV). Symptoms of cervical cancer may include abnormal vaginal bleeding, pain in the pelvic area (between the stomach and thighs), or an unusual discharge from the vagina.

Risk factors include the following:

  • Having an HPV infection
    • Women get HPV through sexual activity with a partner who has HPV—screening tests and the HPV vaccine help with prevention
  • Having multiple sexual partners
  • Having one sexual partner who is high risk (has an HPV infection or many sexual partners)
  • Smoking
  • Weakened immune system
  • Family history of cervical cancer
Sources: Centers for Disease Control and Prevention, American Cancer Society, American Cancer Society, American Cancer Society

Recruiting trials

STATUS Recruiting

ASCENT-GYN-01

A phase 3 clinical trial evaluating the safety and effectiveness of sacituzumab govitecan in patients with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy (GOG-3104/ENGOT-en26).

More patient support and resources

Patients can find additional help and educational information from the following organizations:

ECANA - The Endometrial Cancer Action Network for African Americans /-/media/project/gileadclinicaltrial/lung-cancer/advocacy-groups/link-icon.svg

SHARE Cancer Support /-/media/project/gileadclinicaltrial/lung-cancer/advocacy-groups/link-icon.svg

Facing Our Risk of Cancer Empowered /-/media/project/gileadclinicaltrial/lung-cancer/advocacy-groups/link-icon.svg

Cancer Support Community /-/media/project/gileadclinicaltrial/lung-cancer/advocacy-groups/link-icon.svg

CancerCare /-/media/project/gileadclinicaltrial/lung-cancer/advocacy-groups/link-icon.svg

Gilead is not responsible for the security, privacy, or other policies or practices on any of the third-party websites. These links are to external third-party sites not affiliated with or controlled by Gilead.

Your Questions Answered

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

YOUR QUESTIONS ANSWERED

FAQ Topic:
ALL Clinical Trial Basics Safety and Security Trial Terms Defined The Clinical Trial

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

All trials have different timelines due to various factors, such as the trial phase, study design, treatment duration or health condition being studied. During the consent process before enrolling, the research team will explain the specifics about the trial.
Due to the many differences in insurance plans across the country, coverage in clinical trials can vary. You will learn more about your options during pre-screening.
If you are living with a medical condition, joining a clinical trial may give you access to a new potential treatment before it is publicly available. Just as importantly, it can help researchers understand how this potential treatment affects the body and increase their knowledge about the disease and how to treat it. Participation can also play a vital role in helping others who have a similar condition, both now and in the future. Healthy volunteers in trials contribute to this medical progress as well by helping understand the effect of the potential treatment and any safety concerns.
As with all medical records, participant privacy and confidentiality in trials are protected by law. Once consent is signed, you will be given a trial code. Your trial records will not include your name or personal identity but will identify you with a trial code. This code can only be tracked back to you via a code key which is held by the responsible physician. Your name or personal identity will never be disclosed.
Yes, participants are volunteers and may withdraw from a clinical trial at any time.
A placebo is an inactive version of an intervention that is not intended to provide any medical benefit. It is designed to look the same as the active intervention, so the participant and research team do not know it is a placebo. The placebo is used by comparison to confirm any effects of the intervention being studied, if no approved intervention is available.
"Standard of care" is an intervention already approved for a specific health condition that is available publicly. Interventions in a clinical trial are still being tested to ensure safety and effectiveness.
Some clinical trials are designed to be "double blind" so both participants and researchers are unaware of which treatment group participants are assigned to. This prevents bias from affecting clinical trial data.
Your informed consent is required before being enrolled in a trial. This means you have been provided all relevant information about the study design, how you will participate, your right to withdraw at any time, study alternatives, your personal data protection and the associated risks and benefits. Informed consent is designed to protect patient safety and privacy.
Under FDA regulations, an Institutional Review Board (IRB) is a group that has been formally designated to review and monitor research at a hospital or institution involving human participants. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in, or disapprove research.
Participants are always welcome to visit their usual healthcare providers during a trial. Sometimes, it is important for healthcare providers to collaborate with the research team to ensure success.
After your participation ends, the study may continue for months or years. Once final results from all participants are compiled and analyzed, they are often published publicly. Clinical study report (CSR) synopses and plain language summaries (PLSs) may be made available for certain studies. Check with your clinical trial site or send an email to [email protected] to learn more.
There are a wide variety of professionals involved with any clinical trial, all of whom are vital to ensuring safety and success. The principal investigator, or PI, leads the trial and directs the team of doctors, nurses and other healthcare workers. The clinical trial coordinator manages day-to-day activities and is the main contact for participants. Many clinical trials also have an independent Data and Safety Monitoring Board (DSMB) who periodically reviews data to ensure participant safety, and sometimes effectiveness.
If you don’t qualify because you don’t meet the trial criteria, consider discussing other options with your healthcare provider or the patient’s physician would need to submit a managed access request based on the eligibility. Click here to learn more.